DCF Tool

NRC

National Research Corp – Research and Development in Biotechnology
nrc health (nasdaq:nrcia and nrcib) has helped healthcare organizations illuminate and improve the moments that matter to patients, residents, physicians, nurses, and staff for 35 years. our empathetic heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for, and in turn, design experiences that inspire loyalty and trust. for more information call 800-388-4264, write to info@nrchealth.com, or visit www.nrchealth.com.
Analysis Results
Intrinsic Value $37.47
Latest Price $44.87
Relative Value 20% overvalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 9.2%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 7.4%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 9.2%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 41.0 38.1
2024 44.7 38.8
2025 48.8 39.5
2026 53.3 40.1
2027 58.2 40.8
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 1110 million. This corresponds to a present value of 723 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 197 million. Adding in the terminal value gives a total present value of 920 million.

There are presently 24.6 million outstanding shares, so the intrinsic value per share is 37.47.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 43,716,000
Current Cash 25,026,000
Current Liabilities 33,417,000
Current Debt 4,491,000
Non-Cash Working Capital (NCWC) -10,236,000
Change in NCWC 6,528,000
EBIT 46,543,000
Tax Provision 11,015,000
Depreciation and Amortization 5,277,000
Capital Expenditure -9,835,000
Unlevered Free Cash Flow 36,538,898
Current Assets 73,707,000
Current Cash 54,361,000
Current Liabilities 40,388,000
Current Debt 4,278,000
Non-Cash Working Capital (NCWC) -16,764,000
Change in NCWC -8,566,000
EBIT 50,270,000
Tax Provision 11,155,000
Depreciation and Amortization 6,374,000
Capital Expenditure -5,514,000
Unlevered Free Cash Flow 31,030,673
Current Assets 54,112,000
Current Cash 34,690,000
Current Liabilities 31,681,000
Current Debt 4,061,000
Non-Cash Working Capital (NCWC) -8,198,000
Change in NCWC 9,939,000
EBIT 42,144,000
Tax Provision 4,207,000
Depreciation and Amortization 7,505,000
Capital Expenditure -3,984,000
Unlevered Free Cash Flow 51,328,315
Current Assets 29,157,000
Current Cash 13,517,000
Current Liabilities 38,155,000
Current Debt 4,378,000
Non-Cash Working Capital (NCWC) -18,137,000
Change in NCWC 9,682,000
EBIT 43,035,000
Tax Provision 8,113,000
Depreciation and Amortization 5,539,000
Capital Expenditure -4,662,000
Unlevered Free Cash Flow 44,977,228
Current Assets 28,410,000
Current Cash 12,991,000
Current Liabilities 47,109,000
Current Debt 3,871,000
Non-Cash Working Capital (NCWC) -27,819,000
Change in NCWC -14,173,000
EBIT 35,275,000
Tax Provision 4,662,000
Depreciation and Amortization 5,463,000
Capital Expenditure -5,971,000
Unlevered Free Cash Flow 15,855,976
Current Assets 52,259,000
Current Cash 34,733,000
Current Liabilities 32,310,000
Current Debt 1,138,000
Non-Cash Working Capital (NCWC) -13,646,000
Change in NCWC 1,059,000
EBIT 34,219,000
Tax Provision 11,340,000
Depreciation and Amortization 4,586,000
Capital Expenditure -4,818,000
Unlevered Free Cash Flow 23,727,169
Current Assets 47,065,000
Current Cash 33,021,000
Current Liabilities 31,514,000
Current Debt 2,765,000
Non-Cash Working Capital (NCWC) -14,705,000
Change in NCWC 13,024,000
EBIT 31,197,000
Tax Provision 10,838,000
Depreciation and Amortization 4,225,000
Capital Expenditure -3,973,000
Unlevered Free Cash Flow 33,689,957
Current Assets 56,111,000
Current Cash 42,145,000
Current Liabilities 44,171,000
Current Debt 2,476,000
Non-Cash Working Capital (NCWC) -27,729,000
Change in NCWC -15,428,000
EBIT 26,447,000
Tax Provision 9,750,000
Depreciation and Amortization 4,109,000
Capital Expenditure -2,939,000
Unlevered Free Cash Flow 2,764,356
Current Assets 53,188,000
Current Cash 40,042,000
Current Liabilities 27,926,000
Current Debt 2,479,000
Non-Cash Working Capital (NCWC) -12,301,000
Change in NCWC -5,363,000
EBIT 28,296,000
Tax Provision 9,936,000
Depreciation and Amortization 3,804,000
Capital Expenditure -2,492,000
Unlevered Free Cash Flow 14,236,846
Current Assets 36,474,000
Current Cash 22,092,000
Current Liabilities 23,690,000
Current Debt 2,370,000
Non-Cash Working Capital (NCWC) -6,938,000
Change in NCWC 293,000
EBIT 24,806,000
Tax Provision 9,004,000
Depreciation and Amortization 3,732,000
Capital Expenditure -2,188,000
Unlevered Free Cash Flow 17,522,074
Current Assets 23,815,000
Current Cash 8,286,000
Current Liabilities 35,298,000
Current Debt 12,538,000
Non-Cash Working Capital (NCWC) -7,231,000
Change in NCWC 1,252,000
EBIT 22,719,000
Tax Provision 7,139,000
Depreciation and Amortization 4,699,000
Capital Expenditure -2,348,000
Unlevered Free Cash Flow 19,018,404

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.